# Lonza Biologics, Inc. - Inspection Records Source: https://www.keypedia.com/companies/lonza-biologics-inc/f9882ce5-d92a-4c88-916e-8f4e6d1f2aff > Inspection records and compliance data for Lonza Biologics, Inc. in Portsmouth, New Hampshire. Access full analysis and detailed observations. --- ## Details - Name: Lonza Biologics, Inc. - FEI Number: 3001451441 - City: Portsmouth - State: New Hampshire - Country Name: United States - Address Line 1: 101 International Dr - Zip Code: 03801 ## Related Documents - [483 - Lonza Biologics, Inc. - 2026-04-16](https://www.keypedia.com/records/483/lonza-biologics-inc/7b621acc-25b2-419b-b47c-63946c125023) — source: FDA, date: April 16, 2026 - [FDA Inspection 1312718 - Lonza Biologics, Inc. - 2026-04-16](https://www.keypedia.com/records/fda_inspections/lonza-biologics-inc/ed1a184f-48bf-4bed-8f91-879eb015a451) — source: FDA, date: April 16, 2026 - [FDA Inspection 1312718 - Lonza Biologics, Inc. - 2026-04-16](https://www.keypedia.com/records/fda_inspections/lonza-biologics-inc/5bbfa47f-509d-40b8-bed0-301a8269c65e) — source: FDA, date: April 16, 2026 - [483 - Lonza Biologics, Inc. - 2026-02-06](https://www.keypedia.com/records/483/lonza-biologics-inc/6673b307-3165-470e-bad9-c55bdebe90ed) — source: FDA, date: February 6, 2026 - [FDA Inspection 1304046 - Lonza Biologics, Inc. - 2026-02-06](https://www.keypedia.com/records/fda_inspections/lonza-biologics-inc/f423c98c-ca42-48ca-aa3a-6cfd4e863518) — source: FDA, date: February 6, 2026 - [FDA Inspection 1304046 - Lonza Biologics, Inc. - 2026-02-06](https://www.keypedia.com/records/fda_inspections/lonza-biologics-inc/6829aae3-393f-4927-a6eb-2cdeb1a281e4) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 6, 2026 - [483 - Lonza Biologics, Inc. - 2025-06-06](https://www.keypedia.com/records/483/lonza-biologics-inc/cf15e3d3-5f91-42e8-9b9d-a5cece43b8c8) — source: FDA, date: June 6, 2025 - [483 - Lonza Biologics, Inc. - 2025-06-06](https://www.keypedia.com/records/483/lonza-biologics-inc/b183451f-e08e-4fc2-b16f-6016c1be5c25) — source: FDA, date: June 6, 2025 - [483 - Lonza Biologics, Inc. - 2025-06-06](https://www.keypedia.com/records/483/lonza-biologics-inc/7e2c12cc-7bee-4578-9e3c-7e55036f3e8e) — source: FDA, date: June 6, 2025 - [FDA Inspection 1269735 - Lonza Biologics, Inc. - 2025-06-06](https://www.keypedia.com/records/fda_inspections/lonza-biologics-inc/764dd13f-c7b5-4dc4-a6d1-c66b08767132) — source: FDA, date: June 6, 2025 - [FDA Inspection 1246345 - Lonza Biologics, Inc. - 2024-07-12](https://www.keypedia.com/records/fda_inspections/lonza-biologics-inc/f5daf7e2-8fee-4f83-b20e-a0a824ab2a8c) — source: FDA, date: July 12, 2024 - [483 - Lonza Biologics, Inc. - 2024-03-07](https://www.keypedia.com/records/483/lonza-biologics-inc/a5417b6a-1ebe-4cd5-8ba7-eae412f0931f) — source: FDA, date: March 7, 2024 - [FDA Inspection 1232144 - Lonza Biologics, Inc. - 2024-03-07](https://www.keypedia.com/records/fda_inspections/lonza-biologics-inc/27bf4b1b-9774-4fae-ab31-cccbdc39d416) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 7, 2024 - [FDA Inspection 1232144 - Lonza Biologics, Inc. - 2024-03-07](https://www.keypedia.com/records/fda_inspections/lonza-biologics-inc/d26d327b-7e5e-44dc-a11f-5a0ed641f62d) — classification: No Action Indicated (NAI), source: FDA, date: March 7, 2024 - [483 - Lonza Biologics, Inc. - 2023-07-21](https://www.keypedia.com/records/483/lonza-biologics-inc/868ee773-89d9-4285-aa55-f226970279fa) — source: FDA, date: July 21, 2023 - [FDA Inspection 1210690 - Lonza Biologics, Inc. - 2023-07-21](https://www.keypedia.com/records/fda_inspections/lonza-biologics-inc/fa6c0e5e-762e-44f9-b5cd-483c8003242f) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 21, 2023 - [483 - Lonza Biologics, Inc. - 2021-10-22](https://www.keypedia.com/records/483/lonza-biologics-inc/6e82b09e-669e-408f-9fb6-6063c2bbc0b0) — source: FDA, date: October 22, 2021 - [EIR - Lonza Biologics, Inc. - 2020-11-03](https://www.keypedia.com/records/eir/lonza-biologics-inc/3d44ec3c-8d8b-4191-86f7-37a1e679a7ab) — source: FDA, date: November 3, 2020 - [483 - Lonza Biologics, Inc. - 2020-11-03](https://www.keypedia.com/records/483/lonza-biologics-inc/1c4dc8ba-78a2-4438-b100-d4cfaa927f37) — source: FDA, date: November 3, 2020 - [FDA Inspection 1028939 - Lonza Biologics, Inc. - 2017-09-21](https://www.keypedia.com/records/fda_inspections/lonza-biologics-inc/db419acd-b0d3-4e28-a649-9f42bc3edea4) — classification: No Action Indicated (NAI), source: FDA, date: September 21, 2017 ## Related Companies - [Biogen MA Inc.](https://www.keypedia.com/companies/biogen-ma-inc/85b778d2-1e69-485d-9e93-05c656646fa2) - [GlaxoSmithKline dba Human Genome Sciences Inc](https://www.keypedia.com/companies/glaxosmithkline-dba-human-genome-sciences-inc/c3dd2e54-125d-4d56-b0dc-18cb333074cc) - [Bachem Americas, Inc.](https://www.keypedia.com/companies/bachem-americas-inc/f0157d2d-6b0c-4b13-afd4-551c2ab94aad) - [Solara Active Pharma Sciences Limited](https://www.keypedia.com/companies/solara-active-pharma-sciences-limited/8f3f8236-f49d-43e3-84af-2cb404fb8264) - [Spark Therapeutics, Inc.](https://www.keypedia.com/companies/spark-therapeutics-inc/a5518493-a117-41d3-862d-96d5a5d3b6dd) - [Organo Sintesis, S.A. De C.V.](https://www.keypedia.com/companies/organo-sintesis-sa-de-cv/0d8f4d8d-0fbd-4c4a-8362-439c74e4f37d) - [UQUIFA Mexico, S.A. de C.V.](https://www.keypedia.com/companies/uquifa-mexico-sa-de-cv/8523a240-e52a-495e-a781-e12c6412dc69) - [AGILENT TECHNOLOGIES INC./US](https://www.keypedia.com/companies/agilent-technologies-incus/f39880d4-233e-44bc-9a9e-56d1f9b48065) - [MSN Laboratories Private Limited, Unit-II](https://www.keypedia.com/companies/msn-laboratories-private-limited-unit-ii/539d7af5-94e6-4abe-b01b-fa911be84d2a) - [Apitoria Pharma Private Limited](https://www.keypedia.com/companies/apitoria-pharma-private-limited/3fa64839-667a-4ce5-930b-a1935f0c2b38) ## Related Officers - [Jacek Cieslak](https://www.keypedia.com/people/jacek-cieslak/81b12add-49f1-4dfd-bcb1-60bc5b212b68) - [Senior Regulatory Specialist](https://www.keypedia.com/people/wayne-e-seifert/e92e1f10-c61e-4b08-9156-25907e5e2942) - [Wayne Seifert, Senior Regulatory Specialist](https://www.keypedia.com/people/wayne-seifert-senior-regulatory-specialist/7b488047-5171-4676-b3b9-0409cf1522e7) - [FDA_PERSONNEL](https://www.keypedia.com/people/pete-amin/7f032e7a-1dfc-4240-ba8d-2bba5f7e5b6b) - [Debra M. Emerson, Investigator](https://www.keypedia.com/people/debra-m-emerson-investigator/93c43434-31cb-4fab-a626-696ed99fe08f)